MedTrace Logo

Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols.

NCT02857361 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-08-19

No results posted yet for this study

Summary

The study will look at whether it is preferable to administer two wafers simultaneously or separately.

Conditions

Interventions

DRUG

Sublingual ketamine wafers

Two sublingual ketamine 25 mg wafers

Sponsors & Collaborators

  • iX Biopharma Ltd.

    lead OTHER

Principal Investigators

  • Sam Salman, MD · iX Biopharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02857361 on ClinicalTrials.gov